Clinical Trials Logo

Kidney Cancer clinical trials

View clinical trials related to Kidney Cancer.

Filter by:

NCT ID: NCT00016237 Completed - Lung Cancer Clinical Trials

Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment

Start date: December 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Interleukin-2 combined with a monoclonal antibody may be an effective treatment for kidney, bladder, or lung cancer. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 combined with a monoclonal antibody in treating patients who have kidney, bladder, or lung cancer that has not responded to previous treatment.

NCT ID: NCT00014183 Completed - Kidney Cancer Clinical Trials

ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer

Start date: January 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of kidney cancer. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have recurrent or stage IV kidney cancer.

NCT ID: NCT00012337 Completed - Kidney Cancer Clinical Trials

ZD 1839 in Treating Patients With Metastatic Kidney Cancer

Start date: January 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Drugs such as ZD 1839 may interfere with the growth factors and cause tumor cells to die. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have metastatic kidney cancer.

NCT ID: NCT00011973 Completed - Kidney Cancer Clinical Trials

Chemotherapy in Treating Patients With Advanced Kidney Cancer

Start date: December 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have advanced kidney cancer.

NCT ID: NCT00010283 Completed - Breast Cancer Clinical Trials

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

Start date: July 2000
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the esophagus, stomach, small intestine, or colon.

NCT ID: NCT00006968 Completed - Kidney Cancer Clinical Trials

Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer

Start date: September 2000
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of pentostatin followed by peripheral stem cell transplantation in treating patients who have advanced kidney cancer.

NCT ID: NCT00006864 Completed - Kidney Cancer Clinical Trials

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Start date: July 2000
Phase: Phase 4
Study type: Interventional

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase IV trial to study the effectiveness of interleukin-2 in treating patients who have metastatic kidney cancer.

NCT ID: NCT00006483 Completed - Metastatic Cancer Clinical Trials

Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung

Start date: October 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may be an effective treatment for patients with kidney cancer that has spread to the lung. PURPOSE: Phase II trial to study the effectiveness of sargramostim in treating patients who have kidney cancer that has spread to the lung.

NCT ID: NCT00006384 Completed - Kidney Cancer Clinical Trials

SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

Start date: November 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: SU5416 may stop the growth of kidney cancer by stopping blood flow to the tumor. Interferon alfa-2b may interfere with the growth of the cancer cells. Combining interferon alfa-2b with SU5416 may be an effective treatment for kidney cancer. PURPOSE: Phase II trial to study the effectiveness of combining SU5416 and interferon alfa-2b in treating patients who have unresectable or metastatic kidney cancer.

NCT ID: NCT00006255 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Magnetic Resonance Imaging-guided Thermal Radiofrequencey Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases

Start date: April 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Radiofrequency ablation uses high-frequency electric current to heat and kill tumor cells. Magnetic resonance imaging-guided radiofrequency ablation may an effective treatment for primary kidney cancer, liver metastases, or other solid tumors. PURPOSE: Phase II trial to study the effectiveness of magnetic-resonance-guided radiofrequency ablation in treating patients who have primary kidney cancer, liver metastases, or other solid tumors.